Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.
| Revenue (Most Recent Fiscal Year) | $263.40M |
| Net Income (Most Recent Fiscal Year) | $-198.90M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.26 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.82 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -10.75% |
| Net Margin (Trailing 12 Months) | -10.92% |
| Return on Equity (Trailing 12 Months) | -7.74% |
| Return on Assets (Trailing 12 Months) | -4.11% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.58 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.58 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $8.17 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.14 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.77 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.66 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 72.99M |
| Free Float | 69.54M |
| Market Capitalization | $539.41M |
| Average Volume (Last 20 Days) | 2.05M |
| Beta (Past 60 Months) | 2.20 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.73% |
| Percentage Held By Institutions (Latest 13F Reports) | 95.19% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |